



## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

### **Formulary Immune Globulins:**

Gamastan S-D, Gammagard Liquid, Gammagard S-D, Gamunex-C, Hizentra

### **Non-Formulary Immune Globulins:**

Bivigam, Carimune NF Nanofiltered, Cuvitru, Gamastan, Gammaplex, Hyqvia, Octagam, Privigen, Xembify, Asceniv, Cutaquig, Panzyga

### **Requests for Non-Formulary agents require trial and/or failure of ALL Formulary agents**

#### **Authorization Guidelines:**

Documentation of ALL the following:

- I. The dose prescribed, frequency of use and duration of therapy is within the Food and Drug Administration (FDA)-approved range for the indication or is supported by compendia/peer-reviewed literature
- II. Request is not for experimental/investigational use or for a clinical trial
- III. Products are not interchangeable, selection of product should be based on member factors including diagnosis, past history and individual comorbidities
- IV. The use of parenteral immune globulin therapy is approved for members with any of the following conditions:
  1. Primary immunodeficiencies
    - 1.1 Common Variable Immunodeficiency (CVID)
    - 1.2 Congenital agammaglobulinemia
    - 1.3 Hyper Immunoglobulin M (IgM) syndromes
    - 1.4 Hypogammaglobulinemia
    - 1.5 X-linked Immunodeficiency with hyperimmunoglobulin (elevated or normal Immunoglobulin M (IgM))
    - 1.6 Immunodeficiency with thymoma (Good syndrome)
    - 1.7 Severe Combined Immunodeficiency (SCID)
    - 1.8 Selective Immunoglobulin G (IgG) subclass deficiencies (with evidence of recurrent infections)
    - 1.9 Wiscott-Aldrich Syndrome
    - 1.10 X-linked agammaglobulinemia
      - Medical records and clinical notes showing the following will be required for approval:
        - Laboratory confirmation of immune globulin deficiency
        - Persistent infections despite antibiotic prophylaxis
        - Documented lack of ability to mount immunologic response to antigenic challenge
  2. B-cell chronic lymphocytic leukemia (prevention of recurrent bacterial infections)
    - Immunoglobulin G (IgG) level less than 400 mg/dl; and
    - One (1) severe bacterial infection within preceding 6 months or 2 or more bacterial infections in 1 year or evidence of specific antibody deficiency



## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

3. Multiple myeloma
  - Immunoglobulin G (IgG) less than 500 mg/dl and recurrent bacterial infections should be documented for immune globulin treatment
4. Bone marrow transplantation (prevention of infections)
  - Bone marrow transplant within last 100 days
  - Documented severe hypogammaglobulinemia (Immunoglobulin G (IgG) less than 400 mg/dl)
5. Idiopathic Thrombocytopenic Purpura (ITP) (immune thrombocytopenia)
  - Other causes of thrombocytopenia have been ruled out
  - Idiopathic Thrombocytopenic Purpura (ITP) (Adults)
    - Unresponsive to corticosteroid therapy; and
    - Documentation of one of the following:
      - Management of acute bleeding due to severe thrombocytopenia (platelet counts less than 30,000/ $\mu$ l); or
      - To increase platelet counts prior to invasive major surgical procedures (e.g., splenectomy), or
      - To defer or avoid splenectomy; or
      - In members with severe thrombocytopenia (platelet counts less than 20,000/ $\mu$ l) considered to be at risk for intra-cerebral hemorrhage.
  - Idiopathic Thrombocytopenic Purpura (ITP) (Chronic Refractory)
    - Duration of illness of greater than 6 months; and
    - No concurrent illness/disease explaining thrombocytopenia; and
    - Prior treatment with corticosteroids and splenectomy has failed or member is at high-risk for post-splenectomy sepsis
  - Idiopathic Thrombocytopenic Purpura (ITP) (Pediatrics)
    - Acute Idiopathic Thrombocytopenic Purpura (ITP):
      - IVIG as initial therapy if platelet count less than 20,000/ $\mu$ l, especially when member has emergency bleeding or is at risk for severe life-threatening bleeding; or
      - Severe thrombocytopenia (platelet counts less than 20,000/ $\mu$ l) considered to be at risk for intra-cerebral hemorrhage.
    - Chronic Idiopathic Thrombocytopenic Purpura (ITP):
      - Member has low platelet count or is symptomatic; and
      - Failure of other therapies, or
      - Member is a high risk for post-splenectomy sepsis
  - Idiopathic Thrombocytopenic Purpura (ITP) (Pregnancy)
    - Refractory to steroids with platelet counts less than 10,000/ $\mu$ l in the 3rd trimester;  
or



## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

- Platelet counts less than 30,000/ $\mu$ l associated with bleeding before vaginal delivery or C-section; or
  - Pregnant member with prior history of delivery with autoimmune thrombocytopenia; or
  - Pregnant member who have platelet counts less than 50,000/ $\mu$ l during the current pregnancy; or
  - Pregnant member with past history of splenectomy
6. Chronic inflammatory demyelinating polyneuropathy
    - Documentation of symmetric or focal neurologic deficits with slowly progressive or relapsing course over 2 months or longer (with neurophysiological abnormalities)
  7. Multifocal motor neuropathy
  8. Kawasaki disease (prevention of coronary artery aneurisms)
  9. Human Immunodeficiency infection (reduction of serious opportunistic infections in pediatric members)
    - Member is less than 13 years of age;
    - Immunoglobulin G (IgG) level is less than 400 mg/dl
  10. Guillain-Barre Syndrome (GBS) and Guillain-Barre Syndrome (GBS) variants (infective polyneuritis (includes Guillain-Barre Syndrome (GBS) variants: Miller-Fisher syndrome (MFS), pan autonomic polyneuropathy, acute pandysautonomia, acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN)))
    - Severe Guillain-Barre syndrome with significant weakness such as inability to stand or walk without aid, respiratory or bulbar weakness, or Miller-Fisher syndrome (MFS); and
    - The disorder has been diagnosed during the first 2 weeks of the illness; and
    - Immune globulin therapy is initiated within one month of symptom onset
  11. Relapsing-remitting multiple sclerosis (RRMS)
    - Documentation of the following severe manifestations of relapsing-remitting multiple sclerosis (RRMS) (not primary or secondary progressive multiple sclerosis (MS)); and
    - Documentation of trial and failure of standard approaches (for example, interferons (Betaseron, Avonex, Rebif), glatiramer (Copaxone)), or they are contraindicated.
  12. Graves ophthalmopathy
  13. Autoimmune neutropenia, refractory
    - Documentation that treatment with Granulocyte-Colony Stimulating Factors (G-CSF) is not appropriate.
  14. Autoimmune hemolytic anemia, refractory
    - Documentation of an inadequate response or contraindication to corticosteroids or splenectomy



## **Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins**

15. Polymyositis, dermatomyositis
  - Documentation of trial and failure of corticosteroids (for example, prednisone); and trial of an immunosuppressant (e.g., methotrexate, azathioprine)
16. Streptococcal and staphylococcal toxic shock syndrome or toxic necrotizing fasciitis due to group A streptococcus
17. Moersch-Woltmann (Stiff-man) syndrome
  - Documentation of trial and failure with benzodiazepines, baclofen, gabapentin, valproate, tiagabine, or levetiracetam
18. Myasthenia Gravis
  - Documentation of treatment of acute myasthenic crisis with decompensation (respiratory failure, or disabling weakness requiring hospital admission)).
  - Documentation of trial and failure of other therapies such as azathioprine, cyclosporine and cyclophosphamide
19. Birdshot (vitiligenous) retinochoroidopathy
  - Documentation of trial and failure to immunosuppressive agents (for example, corticosteroids, cyclosporine)
20. Enteroviral meningoencephalitis
21. Neonatal alloimmune thrombocytopenia (NAIT)
22. Neonatal hemochromatosis prophylaxis
  - Documentation that member is pregnant with a history of pregnancy that ended in neonatal hemochromatosis
23. Autoimmune mucocutaneous blistering diseases
  - i. Pemphigus vulgaris
  - ii. Pemphigus foliaceus
  - iii. Bullous pemphigoid
  - iv. Mucous membrane pemphigoid
  - v. Epidermolysis bullosa acquisita
    - The condition is rapidly progressing, extensive or debilitating; and
    - Corticosteroids or immuno-suppressive agents have failed, or member has experienced significant complications from standard treatment, such as diabetes or steroid-induced osteoporosis.
24. Acquired red cell aplasia
25. Parvovirus B19 infection, chronic, with severe anemia
26. Human Immunodeficiency Virus (HIV)-associated thrombocytopenia:
  - Significant bleeding in thrombocytopenic members or platelet count less than 20000/ $\mu$ l
27. Toxic epidermal necrolysis and Steven-Johnson syndrome
28. Preparation for thymoma surgery (to prevent myasthenia exacerbation)



## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

29. Opsoclonus-myoelonus
30. Paraneoplastic opsoclonus-myoelonus-ataxia associated with neuroblastoma
31. Rasmussen encephalitis (Rasmussen's syndrome)
  - Documentation of inadequate response or inability to tolerate anti-epileptic drugs and corticosteroids
32. Lambert-Eaton myasthenic syndrome
  - No response to anticholinesterases (for example, pyridostigmine) and dalfampridine (Ampyra); and
  - Used as an alternative to plasma exchange if weakness is severe or there is difficulty with venous access for plasmapheresis
33. Systemic lupus erythematosus (SLE), for members with severe active systemic lupus erythematosus (SLE) for whom other interventions have been unsuccessful, have become intolerable, or are contraindicated
34. Stem cell or bone marrow transplantation:
  - Prophylaxis in allogeneic or syngeneic transplant members within the first 100 days post-transplant;
  - After 100 days post-transplant, member has Immunoglobulin G (IgG) level less than 400 mg/dL and one of the following:
    - Member has primary immunodeficiency or
    - Member has cytomegalovirus infection, varicella-zoster virus infection, and recurrent bacterial infection
  - Steroid-resistant graft-versus-host disease in bone marrow transplant members 20 years of age or older, in the first 100 days post-transplant, and with Immunoglobulin G (IgG) level less than 400 mg/dl
35. Solid organ transplantation, for allosensitized members undergoing solid organ transplant
36. Severe hyperbilirubinemia in neonates
37. Post-transfusion purpura
  - Decreased platelets (less than 10,000/ $\mu$ l); and
  - 2 to 14 days post-transfusion with bleeding
38. Renal transplantation from live donor with ABO incompatibility or positive cross-match, where a suitable non-reactive live or cadaveric donor is unavailable (preparative regimen)
39. Acute disseminated encephalomyelitis
  - Documentation of trial and failure of intravenous corticosteroid treatment
40. Enteroviral meningoencephalitis

### **Criteria for Renewal:**

- Supporting documentation showing clinical improvement or stabilization of disease state.

### **General Approval Duration:**

- Initial approval: 6 months
- Renewal: 6 months



## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

### **Initial Approval Duration for Specific Indications:**

- Autoimmune hemolytic anemia: 5 days
- Guillain-Barre Syndrome: 5 days
- Idiopathic thrombocytopenic purpura (acute): 5 days
- Post-transfusion purpura: 5 days
- Chronic inflammatory demyelinating polyneuropathy: 3 months

### **Aetna considers parenteral immunoglobulins investigational and experimental for the following indications but not limited to:**

- Isolated Immunoglobulin E (IgE) deficiency
- Isolated Immunoglobulin G<sub>4</sub> (IgG<sub>4</sub>) deficiency
- Selective Immunoglobulin A (IgA) deficiency
- Isolated Immunoglobulin M (IgM) deficiency
- Inclusion body myositis
- Autoimmune diabetes mellitus
- Atopic dermatitis
- Inflammatory bowel disease
- Chronic fatigue syndrome
- Acute rheumatic fever
- Viral load in Human Immunodeficiency Virus infection
- Demyelinating neuropathy associated with monoclonal Immunoglobulin M (IgM)
- Adrenoleukodystrophy
- Amyotrophic lateral sclerosis
- Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS) syndrome
- Paraneoplastic cerebellar degeneration, sensory neuropathy or encephalopathy
- Brachial plexopathy
- Autistic disorders
- Non-steroid dependent asthma
- Dilated cardiomyopathy
- Prevention of infection and acute graft-versus-host disease after bone marrow transplantation
- Cystic fibrosis without hypogammaglobulinemia
- Chronic sinusitis
- Crohn's disease

### **References:**

1. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. The Journal of Allergy and Clinical Immunology. 2017; 139 (3S):S1-S46. <https://doi.org/10.1016/j.jaci.2016.09.023>.

## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

2. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: A review of evidence by members of the primary immunodeficiency committee of the American Academy of Allergy, Asthma and Immunology. 2006; 117 (4): S525-S553. <https://doi.org/10.1016/j.jaci.2006.01.015>.
3. Bivigam® [Prescribing Information]. Biotest Pharmaceuticals Corporation, Boca Raton, FL; June 2013. <https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm334609.pdf>. Accessed May 8, 2018.
4. Carimune®NF [Prescribing Information]. CSL Behring LLC., Kankakee, IL; November 2016. <http://labeling.csلبehring.com/PI/US/Carimune%20NF/EN/Carimune%20NF-Prescribing-Information.pdf>. Accessed May 8, 2018.
5. Cuvitru [Prescribing Information]. Baxalta US Inc., Westlake Village, CA; September 2016. [https://www.shirecontent.com/PI/PDFS/Cuvitru\\_USA\\_ENG.PDF](https://www.shirecontent.com/PI/PDFS/Cuvitru_USA_ENG.PDF). Accessed May 8, 2018.
6. Flebogamma® [Prescribing Information]. Instituto Grifols, S.A., Barcelona, Spain; July 2017. <http://www.grifolsusa.com/documents/10192/63615/flebo10-ft-us-en/f477695f-32d7-4d2b-bdb6-85f49d8eab67>. Accessed May 8, 2018.
7. Gamastan® [Prescribing Information]. Grifols Therapeutics, Inc., Research Triangle Park, NC; June 2017. [http://www.grifolsusa.com/documents/10192/61676/ft\\_gamastan\\_s\\_d\\_immune\\_globulin\\_euu.en/01c7af9f-49f6-4b84-9c36-5593d06bb9fc](http://www.grifolsusa.com/documents/10192/61676/ft_gamastan_s_d_immune_globulin_euu.en/01c7af9f-49f6-4b84-9c36-5593d06bb9fc). Accessed May 14, 2018.
8. Gammagard [Prescribing Information]. Baxalta US Inc., Westlake Village, CA; June 2016. [https://www.shirecontent.com/PI/PDFS/GAMLIQUID\\_USA\\_ENG.pdf](https://www.shirecontent.com/PI/PDFS/GAMLIQUID_USA_ENG.pdf). Accessed May 8, 2018.
9. Gammaked™ [Prescribing Information]. Grifols Therapeutics Inc., Research Triangle Park, NC; September 2016. [http://www.gammaked.com/clientuploads/2016\\_GK\\_PI\\_Web\\_final.pdf](http://www.gammaked.com/clientuploads/2016_GK_PI_Web_final.pdf). Accessed May 8, 2018.
10. Gammaplex 5%® [Prescribing Information]. Bio Products Laboratory Inc., Durham, NC; November 2016. [http://www.gammaplex.com/download/Gammaplex\\_5pct\\_US\\_PI\\_VSUS8PI.pdf](http://www.gammaplex.com/download/Gammaplex_5pct_US_PI_VSUS8PI.pdf). Accessed May 8, 2018.
11. Gammaplex 10%® [Prescribing Information]. Bio Products Laboratory Inc., Durham, NC; 2017. [http://www.gammaplex.com/download/Gammaplex\\_10pct\\_US\\_PI\\_VS10US3PI.pdf](http://www.gammaplex.com/download/Gammaplex_10pct_US_PI_VS10US3PI.pdf). Accessed May 8, 2018.
12. Gamunex®-C [Prescribing Information]. Grifols Therapeutics, Inc., Research Triangle Park, NC; March 2017. <https://www.gamunex-c.com/documents/27482625/27482925/Gamunex-C+Prescribing+Information.pdf/9258bd0f-4205-47e1-ab80-540304c1ff8e>. Accessed May 8, 2018.
13. Hizentra [Prescribing Information]. CSL Behring LLC., Kankakee, IL; March 2018. <http://labeling.csلبehring.com/PI/US/Hizentra/EN/Hizentra-Prescribing-Information.pdf>. Accessed May 8, 2018.
14. Hyqvia [Prescribing Information]. Shire US Inc., Lexington, MA; September 2017. [https://www.shirecontent.com/PI/PDFS/HYQVIA\\_USA\\_ENG.pdf](https://www.shirecontent.com/PI/PDFS/HYQVIA_USA_ENG.pdf). Accessed May 8, 2018.
15. Octagam 5% [Prescribing Information]. Octapharma USA Inc., Hoboken, NJ; October 2014. [https://www.octapharmausa.com/fileadmin/user\\_upload/octagam.com/Prescribing\\_Information\\_Octagam5.pdf](https://www.octapharmausa.com/fileadmin/user_upload/octagam.com/Prescribing_Information_Octagam5.pdf). Accessed May 8, 2018.
16. Octagam 10% [Prescribing Information]. Octapharma USA Inc., Hoboken, NJ; April 2015. [https://www.octapharmausa.com/fileadmin/user\\_upload/octagam.com/Prescribing\\_Information\\_Octagam10.pdf](https://www.octapharmausa.com/fileadmin/user_upload/octagam.com/Prescribing_Information_Octagam10.pdf). Accessed May 8, 2018.
17. Privigen® [Prescribing Information]. CSL Behring LLC., Kankakee, IL; September 2016. <http://labeling.csلبehring.com/PI/US/Privigen/EN/Privigen-Prescribing-Information.pdf>. Accessed May 8, 2018.
18. Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. Department of Health and Human Services. Updated November 2013. Available at: [http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi\\_guidelines\\_pediatrics.pdf](http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf). Accessed May 16, 2018.

## Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins

19. Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. *Lung*. 2009; 187(3):201-206.
20. Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. *J Rheumatol*. 2015; 42(2):236-242.
21. Monshi B, Posch C, Vujic I, et al. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long-term follow-up of 11 patients. *J Am Acad Dermatol*. 2014; 71(4):738-744.
22. Center for Medicare and Medicaid Services (CMS). Intravenous immune globulin for autoimmune mucocutaneous blistering diseases. Decision Memorandum. CPG-00109N. Baltimore, MD: CMS; January 22, 2002. <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=43&NcaName=Intravenous+Immune+Globulin+for+Autoimmune+Mucocutaneous+Blistering+Diseases&NCDId=46&NCSelection=NCA%7CCAL%7CNCD%7CMEDCAC%7CTA%7CMCD&KeyWord=HIV&KeyWordLookUp=Doc&KeyWordSearchType=Exact&kq=true>. Accessed May 16, 2018.
23. Pritchard J, Hughes R, Hadden R, Brassington R. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. *Cochrane Database Syst Rev*. 2016; (11):CD008630.
24. Eftimov F, Winer JB, Vermeulen M, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. *Cochrane Database Syst Rev*. 2009;(1):CD001797.
25. Rayment R, Brunskill SJ, Stanworth S, et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. *Cochrane Database Syst Rev*. 2005; (1):CD004226.
26. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev*. 2007; 21(2 Suppl 1):S9-56.
27. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology*. 2016; 87(4):419-425.
28. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. *Hematology Am Soc Hematol Educ Program*. 2001; 2001(1):392-421.
29. van Schaik IN, van den Berg LH, de Haan R, Vermeulen M. Intravenous immunoglobulin for multifocal motor neuropathy. *Cochrane Database Syst Rev*. 2005 ;(2):CD004429.
30. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2012; 78(13):1009-1015.
31. Dudsek A, Zettl UK. Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis. *J Neurol*. 2006; 253 Suppl 5:V50-V58.
32. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. *Transplantation*. 2000; 70(6):887-895.
33. Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. *Curr Opin Allergy Clin Immunol*. 2003; 3(4):269-274.
34. Prins C, Vittorio C, Padilla RS, et al, Saurat JH, French LE. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: A retrospective, multicenter study. *Dermatology*. 2003; 207(1):96-99.
35. Peterlin BL, Flood W, Kothari MJ. Use of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome. *J Am Osteopath Assoc* 2002; 102:682-4.
36. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. *N Engl J Med* 2012; 367:2015-25.
37. Dalakas MC. The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. *J Neurol* 2005; 252(Suppl 1):119-25.





## **Pharmacy Prior Authorization Clinical Guidelines – Immune Globulins**

38. LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. *Ocul Immunol Inflamm* 2000; 8:49-57.
39. Dwyer JM, Erlendsson K. Intraventricular gamma-globulin for the management of enterovirus encephalitis. *Pediatr Infect Dis J* 1988; 7:S30-3.
40. Alcock GS, Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. *Cochrane Database Syst Rev* 2002; CD003313.
41. Pohl D, Tenenbaum S. Treatment of acute disseminated encephalomyelitis. *Curr Treat Options Neurol* 2012; 14:264-75.